Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Find Stocks Tailored to Your Trading Interests

benzingaproreview-1-1280x720

acf/call-to-action

<p class="has-text-align-left"><strong><a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a></strong></p>





<p></p>

Compare Investing Brokers (USE THIS ONE)

acf/widget-container

acf/compare-products

IBKR Stocks

Plus500 Futures

public.com

Robinhood

TradeZero

eToro Stocks

<p><strong><a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a></strong></p>





<p></p>

Compare Crypto Brokers Homepage

Plus500 Crypto

Kraken

Webull Crypto

FxGlory

eToro

Uphold Crypto

Compare Brokers Table – Benzinga.com

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Oncternal Therapeutics

Oncternal Therapeutics, Inc. - Common Stock

iBio

Dare Bioscience

Fusion Pharmaceuticals

Outlook Therapeutics

Outlook Therapeutics, Inc. - Common Stock

POINT Biopharma Global

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Lantheus Holdings

Eyenovia

Edesa Biotech

Procaps Gr

Genelux

NightHawk Biosciences

electroCore

SCYNEXIS

Icecure Medical

Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Kemp Dolliver's

analyst ratings image

<p>During the last three months, 4 analysts shared their evaluations of Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<p>In the assessment of 12-month price targets, analysts unveil insights for Lantheus Holdings, presenting an average target of $98.75, a high estimate of $100.00, and a low estimate of $95.00. A 12.61% drop is evident in the current average compared to the previous average price target of $113.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708711217_0.png" alt="price target chart" /></p>

<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Lantheus Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Walsh</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Boris Peaker</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kemp Dolliver</td>
<td>Brookline Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lantheus Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lantheus Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Lantheus Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lantheus Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LNTH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lantheus Holdings analyst ratings.</strong></a></p>
<h2>Delving into Lantheus Holdings's Background</h2>
<p>Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.</p>
<h3>Lantheus Holdings: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lantheus Holdings showcased positive performance, achieving a revenue growth rate of <strong>33.71%</strong> as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Lantheus Holdings's net margin excels beyond industry benchmarks, reaching <strong>41.24%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Lantheus Holdings's ROE excels beyond industry benchmarks, reaching <strong>21.09%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lantheus Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>9.23%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Lantheus Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.88</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

Analyst Ratings

LNTH

Assessing Lantheus Holdings: Insights From 4 Financial Analysts

<p>4 analysts have shared their evaluations of Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.75, a high estimate of $100.00, and a low estimate of $95.00. Observing a downward trend, the current average is 18.72% lower than the prior average price target of $121.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1704898842_0.png" alt="price target chart" /></p>

<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Lantheus Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Walsh</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Boris Peaker</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kemp Dolliver</td>
<td>Brookline Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lantheus Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lantheus Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lantheus Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LNTH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lantheus Holdings analyst ratings.</strong></a></p>
<h2>Discovering Lantheus Holdings: A Closer Look</h2>
<p>Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.</p>
<h3>Understanding the Numbers: Lantheus Holdings's Finances</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Lantheus Holdings displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately <strong>33.71%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Lantheus Holdings's net margin excels beyond industry benchmarks, reaching <strong>41.24%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Lantheus Holdings's ROE excels beyond industry benchmarks, reaching <strong>21.09%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lantheus Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>9.23%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Lantheus Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.88</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

Deep Dive Into Lantheus Holdings Stock: Analyst Perspectives (4 Ratings)

Analyst Ratings Newsletter

Don't Miss Your Daily Analyst Rating Email!!!

acf/newsletter-subscription-box

acf/raptive-ad-placement

Investing Channel Sidebar Top

acf/investing-channel-block

acf/news-feed

UBER

What Analysts Are Saying About Uber Technologies Stock

NVTS

The Analyst Verdict: Navitas Semiconductor In The Eyes Of 6 Experts

INTC

Deep Dive Into Intel Stock: Analyst Perspectives (18 Ratings)

RIOT

Decoding 8 Analyst Evaluations For Riot Platforms

Deep Dive Into STMicroelectronics Stock: Analyst Perspectives (4 Ratings)

Navigating 4 Analyst Ratings For NIO

News

Price Target

MSTR

Canaccord Genuity Maintains Buy on MicroStrategy, Raises Price Target to $300

Analyst Ratings Sidebar

Kemp Dolliver's Stock Ratings

Brookline Capital Analyst

Overall Average Return

Smart Score

Overall Average Return Percentile

Number of Ratings

Recent Analyst Stock Rating News

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga